Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Theravance Biopharma, Inc. Director's Dealing 2017

Nov 22, 2017

32537_dirs_2017-11-22_160032e8-e06d-4793-bca1-6a348a12fc45.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Theravance Biopharma, Inc. (TBPH)
CIK: 0001583107
Period of Report: 2017-11-20

Reporting Person: WORBOYS PHILIP D (SVP, Translational Science)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-11-20 Ordinary Shares F 5503 $28.58 Disposed 159129 Direct